Hormone therapy (HT) in Women with Gynecologic Cancers and in Women at High Risk for Developing a Gynecologic Cancer
Recommendations
| Hormone Therapy in Gynecologic Cancer Survivors | |
| Uterine cancer | |
| Early stage endometrial cancer | HT acceptable |
| Advanced stage endometrial cancer | HT not recommended |
| Uterine sarcoma | HT not recommended |
| Ovarian cancer | |
| High grade serous ovarian cancer | HT acceptable |
| Low grade serous and endometrioid ovarian cancer | HT not recommended |
| Cervical cancer | HT acceptable |
| Hormone Therapy in Women at High Risk for Developing Gynecologic Cancer | |
| BRCA mutation with no personal history of breast cancer | HT acceptable |
| BRCA mutation with personal history of breast cancer | HT not recommended |
| Lynch syndrome | HT acceptable |
Recommendation Grading
Overview
Title
Hormone therapy (HT) in Women with Gynecologic Cancers and in Women at High Risk for Developing a Gynecologic Cancer
Authoring Organization
Society of Gynecologic Oncology
Publication Month/Year
May 1, 2020
Last Updated Month/Year
March 16, 2023
Document Type
Guideline
External Publication Status
Published
Country of Publication
US
Inclusion Criteria
Female, Adult
Health Care Settings
Ambulatory, Radiology services
Intended Users
Radiology technologist, nurse, nurse practitioner, physician, physician assistant
Scope
Management, Treatment
Diseases/Conditions (MeSH)
D006176 - Gynecology
Keywords
chemotherapy, cervical cancer, hormone therapy, gynecologic cancers
Source Citation
Sinno AK, Pinkerton J, Febbraro T, Jones N, Khanna N, Temkin S, Iglesias D, Pothuri B. Hormone therapy (HT) in women with gynecologic cancers and in women at high risk for developing a gynecologic cancer: A Society of Gynecologic Oncology (SGO) clinical practice statement: This practice statement has been endorsed by The North American Menopause Society. Gynecol Oncol. 2020 May;157(2):303-306. doi: 10.1016/j.ygyno.2020.01.035. Epub 2020 Feb 15. PMID: 32067815.